Catalyst Pharmaceuticals Settles Patent Litigation with Hetero Labs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy CPRX?
Source: Yahoo Finance
- Settlement Agreement: Catalyst Pharmaceuticals has reached a settlement with Hetero Labs, allowing Hetero to market a generic version of FIRDAPSE starting January 2035, marking a significant advancement in the company's patent litigation and reducing future legal risks.
- Litigation Termination: The agreement results in the termination of all ongoing patent litigation between Catalyst, SERB, and Hetero regarding FIRDAPSE, avoiding the scheduled trial set for May 18, 2026, and allowing the company to allocate legal resources more effectively towards other strategic objectives.
- Market Access Restrictions: Hetero's ability to launch its generic drug in the U.S. will be restricted, requiring FDA approval before it can enter the market, providing Catalyst with a time advantage to protect its market share in the competitive landscape.
- Industry Impact: Catalyst's previous settlements with multiple pharmaceutical companies demonstrate its strong negotiation capabilities and legal strategies, further solidifying its market position in the rare disease treatment sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CPRX
Wall Street analysts forecast CPRX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.150
Low
33.00
Averages
34.00
High
35.00
Current: 31.150
Low
33.00
Averages
34.00
High
35.00
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Catalyst Pharmaceuticals to Announce Q1 Earnings on May 11
- Earnings Announcement: Catalyst Pharmaceuticals is set to release its Q1 2023 earnings on May 11 after market close, with consensus EPS estimate at $0.64, reflecting a 5.9% year-over-year decline, while revenue is projected at $148.18 million, indicating a 5.1% increase, which could significantly impact investor sentiment.
- Historical Performance: Over the past two years, Catalyst has consistently beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability in financial performance and its ability to manage market expectations effectively.
- Estimate Revision Trends: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have experienced three upward and two downward revisions, indicating fluctuations in analyst confidence regarding the company's future performance, which may influence investor decisions.
- Acquisition Interest: Catalyst's stock surged on reports of interest from Angelini Pharma for a $4.1 billion acquisition, which could present new strategic opportunities for the company while potentially impacting its future market positioning and financial health.
See More
Monteverde Law Firm Investigates Catalyst Pharmaceuticals Sale
- Shareholder Recovery: Monteverde & Associates has successfully recovered millions for shareholders, highlighting its recognition as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, which enhances its reputation in securities litigation.
- Transaction Investigation: The firm is currently investigating the sale of Catalyst Pharmaceuticals, Inc. to Angelini Pharma S.p.A., where shareholders are expected to receive $31.50 per share in cash, raising questions about the fairness of this deal in the market.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a law firm's experience in class actions and past recovery successes when selecting legal representation, thereby ensuring they receive professional legal support and boosting shareholder confidence.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to contact Juan Monteverde via email or phone for more information, demonstrating its commitment to client service and transparency.
See More
Catalyst Pharmaceuticals Agrees to $4.1B Acquisition by Angelini Pharma
- Acquisition Agreement: Catalyst Pharmaceuticals has entered into a definitive agreement with Angelini Pharma for a $4.1 billion acquisition, expected to close in Q3 pending shareholder and regulatory approvals, highlighting the company's significant position in industry consolidation.
- Patent Litigation Resolution: The full settlement of FIRDAPSE patent litigation secures U.S. market exclusivity until January 2035, enhancing product market protection and boosting investor confidence in Catalyst's future.
- Strong Stock Performance: Catalyst's stock has risen 24.7% over the past month and 34.6% year-to-date, reflecting positive market sentiment regarding the acquisition and recognition of the company's growth potential.
- Investor Focus: As the deal progresses, investors should monitor the spread between the stock price and the implied deal value, as well as updates on shareholder and regulatory approvals, which will directly impact the transaction's completion and the company's strategic direction.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share, as potential violations of shareholder rights may exist, prompting shareholders to understand their rights and options.
- Transaction Details: TruBridge, Inc. (NASDAQ:TBRG) is being sold to Inventurus Knowledge Solutions, Inc. for $26.25 per share in cash, with Halper Sadeh LLC urging shareholders to be aware of potential legal rights and compensation opportunities.
- Merger Impact: Following the proposed transaction, Modiv Industrial, Inc. (NYSE:MDV) shareholders are expected to own approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC represents investors globally, focusing on legal remedies for securities fraud and corporate misconduct, emphasizing its successful track record in implementing corporate reforms and recovering funds for defrauded investors.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Details: Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the deal at approximately $4.1 billion, with unanimous board approval from both companies, expected to close in Q3 2026, marking Angelini's formal entry into the U.S. market.
- Strategic Importance: This acquisition enhances Angelini's long-term strategy in brain health and rare diseases, as Catalyst's portfolio will integrate with Angelini's brain health assets to build a next-generation rare disease platform, supporting balanced expansion across the U.S. and Europe.
- Financing Arrangement: The deal will be financed with participation from Blackstone funds and international partners, with BNP Paribas serving as Sole Global Coordinator and Underwriter, reflecting strong market confidence and support for the transaction.
- Patent Litigation Resolution: Catalyst also announced a settlement with Hetero Labs Ltd. regarding FIRDAPSE patent litigation, ensuring that a generic version will not be marketed in the U.S. before January 2035, further solidifying its market position and eliminating potential legal risks.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Overview: Angelini Pharma has reached an agreement to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, representing a 28% premium over the 30-day volume-weighted average trading price as of April 22, 2026, marking Angelini Pharma's entry into the U.S. market.
- Strategic Importance: This acquisition not only reinforces Angelini Pharma's commitment to rare diseases but also integrates its presence in the U.S. market with its core business in Europe, expected to drive global growth for the company.
- Financing Structure: The transaction will be financed through a combination of cash and debt, with BNP Paribas acting as the Sole Global Coordinator and Underwriter, ensuring smooth execution of the deal, which is anticipated to close in the third quarter of 2026.
- Product Integration Plans: Following the acquisition, Angelini Pharma intends to merge Catalyst's product portfolio with its expertise in Brain Health to develop a next-generation therapeutic platform for rare diseases, enhancing patient care and innovation capabilities.
See More
Catalyst Pharmaceuticals to Announce Q1 Earnings on May 11
- Earnings Announcement: Catalyst Pharmaceuticals is set to release its Q1 2023 earnings on May 11 after market close, with consensus EPS estimate at $0.64, reflecting a 5.9% year-over-year decline, while revenue is projected at $148.18 million, indicating a 5.1% increase, which could significantly impact investor sentiment.
- Historical Performance: Over the past two years, Catalyst has consistently beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability in financial performance and its ability to manage market expectations effectively.
- Estimate Revision Trends: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have experienced three upward and two downward revisions, indicating fluctuations in analyst confidence regarding the company's future performance, which may influence investor decisions.
- Acquisition Interest: Catalyst's stock surged on reports of interest from Angelini Pharma for a $4.1 billion acquisition, which could present new strategic opportunities for the company while potentially impacting its future market positioning and financial health.
See More
Monteverde Law Firm Investigates Catalyst Pharmaceuticals Sale
- Shareholder Recovery: Monteverde & Associates has successfully recovered millions for shareholders, highlighting its recognition as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, which enhances its reputation in securities litigation.
- Transaction Investigation: The firm is currently investigating the sale of Catalyst Pharmaceuticals, Inc. to Angelini Pharma S.p.A., where shareholders are expected to receive $31.50 per share in cash, raising questions about the fairness of this deal in the market.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a law firm's experience in class actions and past recovery successes when selecting legal representation, thereby ensuring they receive professional legal support and boosting shareholder confidence.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to contact Juan Monteverde via email or phone for more information, demonstrating its commitment to client service and transparency.
See More
Catalyst Pharmaceuticals Agrees to $4.1B Acquisition by Angelini Pharma
- Acquisition Agreement: Catalyst Pharmaceuticals has entered into a definitive agreement with Angelini Pharma for a $4.1 billion acquisition, expected to close in Q3 pending shareholder and regulatory approvals, highlighting the company's significant position in industry consolidation.
- Patent Litigation Resolution: The full settlement of FIRDAPSE patent litigation secures U.S. market exclusivity until January 2035, enhancing product market protection and boosting investor confidence in Catalyst's future.
- Strong Stock Performance: Catalyst's stock has risen 24.7% over the past month and 34.6% year-to-date, reflecting positive market sentiment regarding the acquisition and recognition of the company's growth potential.
- Investor Focus: As the deal progresses, investors should monitor the spread between the stock price and the implied deal value, as well as updates on shareholder and regulatory approvals, which will directly impact the transaction's completion and the company's strategic direction.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share, as potential violations of shareholder rights may exist, prompting shareholders to understand their rights and options.
- Transaction Details: TruBridge, Inc. (NASDAQ:TBRG) is being sold to Inventurus Knowledge Solutions, Inc. for $26.25 per share in cash, with Halper Sadeh LLC urging shareholders to be aware of potential legal rights and compensation opportunities.
- Merger Impact: Following the proposed transaction, Modiv Industrial, Inc. (NYSE:MDV) shareholders are expected to own approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC represents investors globally, focusing on legal remedies for securities fraud and corporate misconduct, emphasizing its successful track record in implementing corporate reforms and recovering funds for defrauded investors.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Details: Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the deal at approximately $4.1 billion, with unanimous board approval from both companies, expected to close in Q3 2026, marking Angelini's formal entry into the U.S. market.
- Strategic Importance: This acquisition enhances Angelini's long-term strategy in brain health and rare diseases, as Catalyst's portfolio will integrate with Angelini's brain health assets to build a next-generation rare disease platform, supporting balanced expansion across the U.S. and Europe.
- Financing Arrangement: The deal will be financed with participation from Blackstone funds and international partners, with BNP Paribas serving as Sole Global Coordinator and Underwriter, reflecting strong market confidence and support for the transaction.
- Patent Litigation Resolution: Catalyst also announced a settlement with Hetero Labs Ltd. regarding FIRDAPSE patent litigation, ensuring that a generic version will not be marketed in the U.S. before January 2035, further solidifying its market position and eliminating potential legal risks.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Overview: Angelini Pharma has reached an agreement to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, representing a 28% premium over the 30-day volume-weighted average trading price as of April 22, 2026, marking Angelini Pharma's entry into the U.S. market.
- Strategic Importance: This acquisition not only reinforces Angelini Pharma's commitment to rare diseases but also integrates its presence in the U.S. market with its core business in Europe, expected to drive global growth for the company.
- Financing Structure: The transaction will be financed through a combination of cash and debt, with BNP Paribas acting as the Sole Global Coordinator and Underwriter, ensuring smooth execution of the deal, which is anticipated to close in the third quarter of 2026.
- Product Integration Plans: Following the acquisition, Angelini Pharma intends to merge Catalyst's product portfolio with its expertise in Brain Health to develop a next-generation therapeutic platform for rare diseases, enhancing patient care and innovation capabilities.
See More
